Aclaris Therapeutics (ACRS) Enterprise Value (2017 - 2025)
Historic Enterprise Value for Aclaris Therapeutics (ACRS) over the last 9 years, with Q3 2025 value amounting to -$95.9 million.
- Aclaris Therapeutics' Enterprise Value rose 2490.57% to -$95.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$95.9 million, marking a year-over-year increase of 2490.57%. This contributed to the annual value of -$113.6 million for FY2024, which is 462.78% up from last year.
- As of Q3 2025, Aclaris Therapeutics' Enterprise Value stood at -$95.9 million, which was up 2490.57% from -$99.8 million recorded in Q2 2025.
- Aclaris Therapeutics' Enterprise Value's 5-year high stood at -$95.9 million during Q3 2025, with a 5-year trough of -$248.6 million in Q2 2022.
- Moreover, its 5-year median value for Enterprise Value was -$128.2 million (2024), whereas its average is -$154.6 million.
- Its Enterprise Value has fluctuated over the past 5 years, first tumbled by 25828.72% in 2021, then soared by 5845.72% in 2023.
- Aclaris Therapeutics' Enterprise Value (Quarter) stood at -$191.4 million in 2021, then dropped by 13.67% to -$217.6 million in 2022, then surged by 45.26% to -$119.1 million in 2023, then rose by 4.63% to -$113.6 million in 2024, then grew by 15.57% to -$95.9 million in 2025.
- Its Enterprise Value was -$95.9 million in Q3 2025, compared to -$99.8 million in Q2 2025 and -$105.3 million in Q1 2025.